PSCH:NSD-PowerShares S&P SmallCap Health Care Portfolio (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 47.07

Change

0.00 (0.00)%

Market Cap

USD 0.18B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the S&P SmallCap 600? Capped Health Care Index. The fund generally will invest at least 90% of its total assets in common stocks of small capitalization U.S. healthcare companies that comprise the underlying index. These companies are principally engaged in the business of providing healthcare-related products, facilities and services, including biotechnology, pharmaceuticals, medical technology and supplies. The fund is non-diversified.

Inception Date: 07/04/2010

Primary Benchmark: S&P Small 600 Cap HealthCare TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.29%

Management Expense Ratio: 0.29 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-31 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Biotechnology ETF 0.47 %

+2.25 (+1.55%)

USD 7.71B
PPH VanEck Pharmaceutical ETF 0.36 %

+0.22 (+0.23%)

USD 0.72B
BBH VanEck Biotech ETF 0.35 %

+1.73 (+0.96%)

USD 0.45B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

+0.98 (+2.14%)

USD 0.14B
GNOM Global X Genomics & Biotechnol.. 0.00 %

+0.34 (+3.10%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

+0.20 (+0.69%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

+0.66 (+4.26%)

USD 0.01B

ETFs Containing PSCH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -63.34% 38% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.34% 38% F 9% A-
Trailing 12 Months  
Capital Gain -62.17% 25% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.17% 25% F 12% F
Trailing 5 Years  
Capital Gain -58.94% 13% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.94% 13% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 3.76% N/A N/A 55% F
Dividend Return 3.77% N/A N/A 51% F
Total Return 0.02% N/A N/A 1% F
Risk Return Profile  
Volatility (Standard Deviation) 29.64% N/A N/A 62% D
Risk Adjusted Return 12.73% N/A N/A 49% F
Market Capitalization 0.18B 67% D+ 48% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.